Capricor Therapeutics, Inc. (NASDAQ:CAPR) has scheduled a conference call for 12th November 2020 at 4:30 PM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.capricor.com
To participate on the live call, please dial 877-451-6152 (United States) or 201-389-0879 Toll Number, with passcode : 13712434
Earnings Expectation
Capricor Therapeutics, Inc. is reporting third quarter earnings results on Thursday 12th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.37 per share from $ 0.21 million in revenue. For the full year, analysts predict revenues of $ 0.24 million, while looking forward to loss of $ 1.46 per share.
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. The companys development stage drug candidates for cardiosphere-derived cells include CAP-1002 that completed phase I/II clinical trial in subjects with DMD; phase I clinical trial for treating heart failure; and phase I/II clinical trial in subjects with myocardial infarction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions.
